Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company that publicly describes its focus as the development of emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and, in some disclosures, FLT3. The Curis news stream highlights clinical progress, financing events, and corporate updates that shape the company’s development plans and capital position.
News about Curis frequently covers clinical data and study milestones for emavusertib. The company has reported interim results from its frontline AML triplet study (emavusertib with venetoclax and azacitidine), updates from the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 trials in PCNSL, AML and high-risk MDS, and presentations at major medical meetings such as the American Society of Hematology (ASH), the Society for Neuro-Oncology (SNO), and ASCO. These releases often describe response measures such as minimal residual disease status and safety observations within defined patient cohorts.
Investors following CRIS news will also see financing and capital markets announcements, including registered direct offerings, concurrent private placements of pre-funded and common warrants, and a PIPE financing involving Series B convertible preferred stock and multiple warrant series. Curis’s news has detailed the structure of these transactions, the gross proceeds, and the stated use of funds for research and development, general corporate purposes, and working capital.
Additional news items address corporate and regulatory developments, such as business updates, quarterly financial results, inducement equity grants, conference participation, and Nasdaq listing compliance notices related to market value of listed securities requirements. For readers tracking Curis, the CRIS news page provides an organized view of these clinical, financial, and listing-related disclosures in one place, allowing users to review how trial data, capital raises, and regulatory interactions evolve over time.
Curis, Inc. (NASDAQ: CRIS) announced positive clinical data from its ongoing Phase 1/2 study of CA-4948, an IRAK-4 inhibitor, for treating relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As of December 16, 2021, CA-4948 was well-tolerated, with no dose-limiting toxicities reported, and showed promising anti-cancer activity with a 40% complete response rate in AML patients with specific mutations. Curis also reported initial positive safety data for CI-8993, a monoclonal antibody targeting VISTA, currently in Phase 1 trials for solid tumors.
Curis, Inc. (NASDAQ: CRIS) announced the appointment of three new executives to enhance its management team as of January 3, 2022. Felix Geissler, M.D., Ph.D., becomes Vice President of Medical Affairs; Kimberly Steinmann, M.D., Vice President of Clinical Development; and Dora Ferrari, Vice President of Clinical Operations. These appointments aim to bolster internal capabilities for advancing clinical drug candidates CA-4948 and CI-8993. The company is focused on developing innovative cancer therapeutics and has collaborations for its drug candidates, including ongoing trials.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, starting at 7:00 a.m. ET. The presentation will be available for on-demand viewing afterward. A live webcast can be viewed in the Investors section of Curis' website and will remain accessible for 90 days. Curis focuses on developing cancer therapeutics, including collaborations on various oncology treatments, such as the IRAK4 inhibitor CA-4948, currently in trials for non-Hodgkin lymphoma and acute myeloid leukemia.
Curis, Inc. (NASDAQ: CRIS) has been added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF, effective before market open on December 20, 2021. Curis focuses on innovative cancer therapeutics, with ongoing clinical trials for several drug candidates, including CA-4948, which has received Orphan Drug Designation for acute myeloid leukemia. The company collaborates with Aurigene and ImmuNext, and their partnership with Genentech commercializes Erivedge for advanced basal cell carcinoma.
Curis, Inc. (NASDAQ: CRIS) announced the appointment of John A. Hohneker, M.D., to its Board of Directors on Dec. 6, 2021. Dr. Hohneker brings over 30 years of biopharmaceutical experience, previously serving as President and CEO of Anokion SA and in leadership roles at Novartis. His expertise will support Curis in accelerating drug candidates, particularly the first-in-class IRAK4 inhibitor, CA-4948, currently in clinical trials for various cancers. This appointment is seen as pivotal for Curis's future growth and potential commercialization of its therapies.
Curis (CRIS) announced its Q3 2021 financial results, reporting a net loss of $11.1 million or $0.12 per share, compared to a loss of $6.0 million for Q3 2020. Revenues grew to $3.0 million from $2.7 million year-over-year. The company continues to advance its clinical trials for CA-4948 in AML, MDS, and B cell cancers, with a significant update expected in January 2022. Operating expenses increased to $13.1 million due to higher R&D costs. As of September 30, 2021, Curis had $149.8 million in cash, ensuring planned operations into 2024.
Curis, Inc. (NASDAQ: CRIS) announced new preclinical data for its investigational monoclonal antibody, CI-8993, at the Society for Immunotherapy of Cancer's 36th Annual Meeting. CI-8993 targets the immune checkpoint molecule VISTA, with a study conducted in collaboration with the Olivia Newton-John Cancer Research Institute confirming its binding properties. Future plans include a clinical trial involving patients with solid tumors. This research aligns with Curis's commitment to advancing cancer therapies and supports ongoing development in immuno-oncology.
Curis, Inc. (NASDAQ: CRIS) announced the first patient has been dosed in the Phase 1/2 clinical trial of CA-4948, an IRAK4 kinase inhibitor, aimed at patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). This study will evaluate CA-4948 in combination with azacitidine and venetoclax, targeting improved treatment options for patients ineligible for intensive chemotherapy. Initial monotherapy results have been promising, and CA-4948 has received Orphan Drug Designation from the FDA.
Curis, Inc. (NASDAQ: CRIS) is set to release its third quarter 2021 financial results on November 9, 2021, after market close. Management will host a conference call at 4:30 PM ET to discuss the results. Curis focuses on innovative cancer therapeutics, holding exclusive licenses for several small molecule antagonists and conducting clinical trials for drugs like CA-4948 in non-Hodgkin's lymphoma and acute myeloid leukemia. Key collaborations include partnerships with Aurigene and Genentech for drug development and commercialization.
Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focused on cancer therapeutics, has announced its participation in virtual events during November and December 2021. Key highlights include:
- Credit Suisse Healthcare Conference on November 8, featuring CEO Jim Dentzer.
- Jefferies Global Healthcare Conference on November 18, where Dentzer will also present.
- B. Riley Oncology Panel on December 1, featuring Robert Martell.
Live webcasts can be viewed on Curis's website, with archived replays available for 90 days.